No cross-resistance or selection of HIV-1 resistant mutants in vitro to the antiretroviral tripeptide glycyl-prolyl-glycine-amide

Antiviral Research

Volumn 61, Issue 2, 2004, Pages 119-124

  Andersson, Elin ^a   Horal, Peter ^a   Vahlne, Anders ^b   Svennerholm, Bo ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Antiretroviral resistance; Glycyl prolyl glycine amide; Tripeptides

Indexed keywords

ANTIRETROVIRUS AGENT; GAG PROTEIN; GLYCYLPROLYLGLYCINAMIDE; LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIPEPTIDE DERIVATIVE; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS RESISTANCE; DRUG EFFICACY; DRUG SENSITIVITY; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; VIRUS ISOLATION; VIRUS MUTANT; VIRUS MUTATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0344304747     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2003.09.003     Document Type: Article

References (39)

1. Balzarini J. Suppression of resistance to drugs targeted to human immunodeficiency virus reverse transcriptase by combination therapy. Biochem. Pharmacol. 58:1999;1-27.
2. Balzarini J., Naesens L., De Clercq E. New antivirals-mechanism of action and resistance development. Curr. Opin. Microbiol. 1:1998;535-546.
3. Berthet-Colominas C., Monaco S., Novelli A., Sibai G., Mallet F., Cusack S. Head-to-tail dimers and interdomain flexibility revealed by the crystal structure of HIV-1 capsid protein (p24) complexed with a monoclonal antibody Fab. EMBO J. 18:1999;1124-1136.
4. Carpenter C.C., Cooper D.A., Fischl M.A., Gatell J.M., Gazzard B.G., Hammer S.M., Hirsch M.S., Jacobsen D.M., Katzenstein D.A., Montaner J.S., Richman D.D., Saag M.S., Schechter M., Schooley R.T., Thompson M.A., Vella S., Yeni P.G., Volberding P.A. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA. 283:2000;381-390.
5. Colgan J., Yuan H.E., Franke E.K., Luban J. Binding of the human immunodeficiency virus type 1 Gag polyprotein to cyclophilin A is mediated by the central region of capsid and requires Gag dimerization. J. Virol. 70:1996;4299-4310.
6. Collier A.C., Coombs R.W., Schoenfeld D.A., Bassett R.L., Timpone J., Baruch A., Jones M., Facey K., Whitacre C., McAuliffe V.J., Friedman H.M., Merigan T.C., Reichman R.C., Hooper C., Corey L. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N. Engl. J. Med. 334:1996;1011-1017.
7. Deeks S.G., Wrin T., Liegler T., Hoh R., Hayden M., Barbour J.D., Hellmann N.S., Petropoulos C.J., McCune J.M., Hellerstein M.K., Grant R.M. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N. Engl. J. Med. 344:2001;472-480.
8. Dianzani F., Antonelli G., Turriziani O., Riva E., Dong G., Bellarosa D. In vitro selection of human immunodefiency virus type 1 resistant to Ro 31-8959 proteinase inhibitor. Antiviral Chem. Chemother. 4:1993;329-333.
9. Fitzon T., Leschonsky B., Bieler K., Paulus C., Schroder J., Wolf H., Wagner R. Proline residues in the HIV-1 NH2-terminal capsid domain: structure determinants for proper core assembly and subsequent steps of early replication. Virology. 268:2000;294-307.
10. Gamble T.R., Yoo S., Vajdos F.F., von Schwedler U.K., Worthylake D.K., Wang H., McCutcheon J.P., Sundquist W.I., Hill C.P. Structure of the carboxyl-terminal dimerization domain of the HIV-1 capsid protein. Science. 278:1997;849-853.
11. Hirsch M.S., Brun-Vézinet F., D'Aquila R.T., Hammer S.M., Johnson V.A., Kuritzkes D.R., Loveday C., Mellors J.W., Clotet B., Conway B., Demeter L.M., Vella S., Jacobsen D.M., Richman D.D. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA. 283:2000;2417-2426.
12. Hoglund S., Su J., Reneby S.S., Vegvari A., Hjerten S., Sintorn I.M., Foster H., Wu Y.P., Nystrom I., Vahlne A. Tripeptide interference with human immunodeficiency virus type 1 morphogenesis. Antimicrob. Agents Chemother. 46:2002;3597-3605.
13. Horal P., Hall W.W., Svennerholm B., Lycke J., Jeansson S., Rymo L., Kaplan M.H., Vahlne A. Identification of type-specific linear epitopes in the glycoproteins gp46 and gp21 of human T-cell leukemia viruses type I and type II using synthetic peptides. Proc. Natl. Acad. Sci. U.S.A. 88:1991;5754-5758.
14. Iroegbu J., Birk M., Lazdina U., Sonnerborg A., Sallberg M. Variability and immunogenicity of human immunodeficiency virus type 1 p24 gene quasispecies. Clin. Diagn. Lab. Immunol. 7:2000;377-383.
15. Japour A.J., Mayers D.L., Johnson V.A., Kuritzkes D.R., Beckett L.A., Arduino J.M., Lane J., Black R.J., Reichelderfer P.S., D'Aquila R.T. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group. Antimicrob. Agents Chemother. 37:1993;1095-1101.
16. LaBranche C.C., Galasso G., Moore J.P., Bolognesi D.P., Hirsch M.S., Hammer S.M. HIV fusion and its inhibition. Antiviral Res. 50:2001;95-115.
17. Larder B.A., Coates K.E., Kemp S.D. Zidovudine-resistant human immunodeficiency virus selected by passage in cell culture. J. Virol. 65:1991;5232-5236.
18. Lawless M.K., Barney S., Guthrie K.I., Bucy T.B., Petteway S.R. Jr., Merutka G. HIV-1 membrane fusion mechanism: structural studies of the interactions between biologically-active peptides from gp41. Biochemistry. 35:1996;13697-13708.
19. Li S., Hill C.P., Sundquist W.I., Finch J.T. Image reconstructions of helical assemblies of the HIV-1 CA protein. Nature. 407:2000;409-413.
20. Little S.J., Daar E.S., D'Aquila R.T., Keiser P.H., Connick E., Whitcomb J.M., Hellmann N.S., Petropoulos C.J., Sutton L., Pitt J.A., Rosenberg E.S., Koup R.A., Walker B.D., Richman D.D. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA. 282:1999;1142-1149.
21. Markowitz M., Mo H., Kempf D.J., Norbeck D.W., Bhat T.N., Erickson J.W., Ho D.D. Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J. Virol. 69:1995;701-706.
22. Perno C.F., Cozzi-Lepri A., Balotta C., Forbici F., Violin M., Bertoli A., Facchi G., Pezzotti P., Cadeo G., Tositti G., Pasquinucci S., Pauluzzi S., Scalzini A., Salassa B., Vincenti A., Phillips A.N., Dianzani F., Appice A., Angarano G., Monno L., Ippolito G., Moroni M., d'Arminio Monforte A. Secondary mutations in the protease region of human immunodeficiency virus and virologic failure in drug-naive patients treated with protease inhibitor-based therapy. J. Infect. Dis. 184:2001;983-991.
23. Pillay D., Taylor S., Richman D.D. Incidence and impact of resistance against approved antiretroviral drugs. Rev. Med. Virol. 10:2000;231-253.
24. Powderly W.G. Long-term exposure to lifelong therapies. J. Acquir. Immune Defic. Syndr. 29(Suppl. 1):2002;S28-S40.
25. Protein sequence database [database online] Bethesda, MD: National Center for Biotechnology Information, 2002. Updated July 5 2002.
26. Reicin A.S., Paik S., Berkowitz R.D., Luban J., Lowy I., Goff S.P. Linker insertion mutations in the human immunodeficiency virus type 1 gag gene: effects on virion particle assembly, release, and infectivity. J. Virol. 69:1995;642-650.
27. Richman D., Shih C.K., Lowy I., Rose J., Prodanovich P., Goff S., Griffin J. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc. Natl. Acad. Sci. U.S.A. 88:1991;11241-11245.
28. Richman D.D. Principles of HIV resistance testing and overview of assay performance characteristics. Antiviral Ther. 5:2000;27-31.
29. Seibert S.A., Howell C.Y., Hughes M.K., Hughes A.L. Natural selection on the gag, pol, and env genes of human immunodeficiency virus 1 (HIV-1). Mol. Biol. E. 12:1995;803-813.
30. Singh A.R., Hill R.L., Lingappa J.R. Effect of mutations in Gag on assembly of immature human immunodeficiency virus type 1 capsids in a cell-free system. Virology. 279:2001;257-270.
31. Soudeyns H., Yao X.I., Gao Q., Belleau B., Kraus J.L., Nguyen-Ba N., Spira B., Wainberg M.A. Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2′-deoxy-3′-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog. Antimicrob. Agents Chemother. 35:1991;1386-1390.
32. Su J., Andersson E., Horal P., Naghavi M.H., Palm A., Wu Y.P., Eriksson K., Jansson M., Wigzell H., Svennerholm B., Vahlne A. The nontoxic tripeptide glycyl-prolyl-glycine amide inhibits the replication of human immunodeficiency virus type 1. J. Hum. Virol. 4:2001a;1-7.
33. Su J., Naghavi M.H., Jejcic A., Horal P., Furuta Y., Wu Y.P., Li S.L., Hall W.W., Goobar-Larsson L., Svennerholm B., Vahlne A. The tripeptide glycyl-prolyl-glycine amide does not affect the early steps of the human immunodeficiency virus type 1 replication. J. Hum. Virol. 4:2001b;8-15.
34. Tang S., Murakami T., Agresta B.E., Campbell S., Freed E.O., Levin J.G. Human immunodeficiency virus type 1 N-terminal capsid mutants that exhibit aberrant core morphology and are blocked in initiation of reverse transcription in infected cells. J. Virol. 75:2001;9357-9366.
35. The EuroGuidelines Group for HIV Resistance 2001. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. AIDS, vol. 15. pp. 309-320.
36. Tisdale M., Kemp S.D., Parry N.R., Larder B.A. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc. Natl. Acad. Sci. U.S.A. 90:1993;5653-5656.
37. Turner B.G., Summers M.F. Structural biology of HIV. J. Mol. Biol. 285:1999;1-32.
38. Vandamme A.-M., Houyez F., Banhegyi D., Clotet B., De Schrijver G., De Smet K.A., Hall W.W., Harrigan R., Hellmann N., Hertogs K., Holtzer C., Larder B., Pillay D., Race E., Schmit J.C., Schuurman R., Schulse E., Sonnerborg A., Miller V. Laboratory guidelines for the practical use of HIV drug resistance tests in patient follow-up. Antiviral Ther. 6:2001;21-39.
39. Zhang W.H., Hockley D.J., Nermut M.V., Morikawa Y., Jones I.M. Gag-Gag interactions in the C-terminal domain of human immunodeficiency virus type 1 p24 capsid antigen are essential for Gag particle assembly. J. Gen. Virol. 77:1996;743-751.